- According to a document,the Bureau of Pharma PSUs of India (BPPI) has found 25 batches of drugs of 18 pharmaceutical companies to be of substandard quality since January 2018.
- While 17 out of the 18 companies are private,one is a public sector unit (PSU) which is the Indian Drugs and Pharmaceuticals Limited (IDPL).
- Of these,seven companies have been blacklisted for two years which means they are barred from supplying generic drugs to Jan Aushadhi scheme.
- Bureau of Pharma PSUs of India (BPPI) is the implementing agency of Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP).
- BPPI was established in 2008 and comes under the Department of Pharmaceuticals.It got registered as an independent society in 2010 under the Societies Registration Act,1860.
- BPPI primarily focuses on coordinating marketing of the generic drugs through the Jan Aushadhi stores and sourcing of medicines from Pharma CPSUs and Private Sector.It also manages the supply chain and ensures proper running of the Jan Aushadhi stores.
- Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) is a campaign launched by the Department of Pharmaceuticals to provide quality medicines at affordable prices to the masses.Jan Aushadhi stores have been set up to provide generic drugs.
- A generic drug is a copy of drug medication created to be the same as an already marketed brand-name drug.It equals in dosage form, safety, strength, route of administration, quality,performance characteristics and intended use.
- Once patents have expired, companies other than the original manufacturer can produce and sell the drug.This usually results in significant reduction in costs.These off-patent drugs are called generics internationally.
8 min read